Allogenic Plasma Eye Drops for Ligneous Conjunctivitis
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Allogenic Plasma Aliquots for ligneous conjunctivitis?
Is it safe to use allogenic plasma eye drops for ligneous conjunctivitis?
How does the treatment Allogenic Plasma Aliquots differ from other treatments for ligneous conjunctivitis?
Allogenic Plasma Aliquots, used as eye drops, are unique because they involve using plasma from donors to treat ligneous conjunctivitis, a rare eye condition. This approach is different from other treatments like heterologous serum or fresh frozen plasma, as it specifically uses plasma components to potentially address the underlying issues related to the condition.12347
What is the purpose of this trial?
This trial uses eye drops made from donated blood plasma to treat patients with a rare eye condition called ligneous conjunctivitis. The eye drops provide a missing protein that helps dissolve harmful build-up on the eyes.
Research Team
Dorothy V Bautista, MD
Principal Investigator
Memorial University of Newfoundland
Eligibility Criteria
This trial is for individuals diagnosed with ligneous conjunctivitis, a rare eye condition, who have Type 1 plasminogen deficiency. It's not suitable for those with other concurrent eye diseases that would interfere with the treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive allogenic plasma aliquots as eye drops to treat recurrences of ligneous conjunctivitis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Allogenic Plasma Aliquots
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dorothy Bautista, MD
Lead Sponsor
Canadian Blood Services
Collaborator